Incyte Corporation

As of June 30, 2026, Incyte Corporation carries a market capitalization of 20.21B, placing it among publicly traded companies globally. Its enterprise value stands at 16.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Incyte Corporation's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Incyte Corporation has 200.98M shares outstanding.

As of June 30, 2026, Incyte Corporation trades at a trailing price-to-earnings ratio of 14.12. The price-to-sales ratio is 3.91, and the price-to-book ratio stands at 3.64.

As of June 30, 2026, Incyte Corporation trades at an EV/EBITDA multiple of 9.91 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.19 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.45 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Incyte Corporation trades at an EV/FCF ratio of 9.53, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 16.27B versus a market cap of 20.21B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Incyte Corporation maintains a current ratio of 4.59, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.60, indicating moderate leverage, while an interest coverage ratio of 807.17 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Incyte Corporation posted a return on equity (ROE) of 30.67, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 27.49 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 23.55, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 30.47, useful for judging operating efficiency across full business cycles. The company generates approximately 1.83M in revenue per employee across its workforce of 2,787.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.38 indicates how many times Incyte Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Incyte Corporation recorded 310.71M in income tax expense. That works out to an effective tax rate of 18.04, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.72B, leaving 1.41B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Incyte Corporation's stock has gained approximately 33.93% over the past 52 weeks. The 50-day moving average sits at 106.27, while the 200-day moving average is 93.28.

Over the twelve months ended June 30, 2026, Incyte Corporation generated 5.09B in revenue and converted that into 1.41B in net income, yielding earnings per share of 6.87. EBITDA reached 1.64B, while operating income came in at 1.61B.

As of June 30, 2026, Incyte Corporation holds 3.97B in cash and equivalents against 33.50M in total debt, resulting in a net debt position of -3.49B. Total book value stands at 5.55B, with working capital of 4.13B providing operational flexibility.

Incyte Corporation produced 1.73B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -26.26M in capital expenditures, free cash flow totaled 1.71B - equivalent to 8.61 per share.

Over the twelve months ended June 30, 2026, Incyte Corporation posted a gross margin of 92.62, reflecting its pricing power and cost economics. The operating margin of 31.61 and net profit margin of 27.71 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 8.27, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -1.19, meaning Incyte Corporation raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Incyte Corporation's most recent stock split took place on September 1, 2000 with a 1:2 split ratio.

As of June 30, 2026, Incyte Corporation has an Altman Z-Score of 11.56, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.